Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGNITE Trial: Lutetium (177Lu) DGUL + Pembrolizumab in mCRPC
NCT07244393Phase 1Recruiting
- Sponsor
- CellBion
- Start
- Jul 2026
- Primary completion
- Apr 2029
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of Lutetium (177Lu) DGUL in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by CellBion. Primary endpoints: Treatment-Emergent Adverse Events, Drug-related Treatment-Emergent Adverse Events and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
Lutetium (177Lu) DGUL
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07244393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244393.